AFT Pharmaceuticals Declares Fully Imputed Final Dividend
AFT Pharmaceuticals Limited (ASX: AFP) announced a fully imputed final dividend for shareholders following its latest financial year results. The company confirmed a total cash distribution of NZ$0.025 per share, with a gross distribution amount of NZ$0.0347 per share. The dividend will be paid on 3 July 2026, while the record date has been set for 19 June 2026.
The distribution will be funded through retained earnings and income available for distribution, with total dividend payments amounting to approximately NZ$2.62 million. The announcement also confirmed that the dividend is fully imputed at 28%, providing additional tax benefits for eligible shareholders. AFT Pharmaceuticals continues to maintain a shareholder-return strategy while supporting business growth across its pharmaceutical operations. The latest dividend declaration reflects the company’s ongoing focus on financial stability and capital management.
The company also disclosed supplementary distribution and withholding tax details as part of the official notice. Investors will closely monitor AFT’s future earnings performance and dividend sustainability amid evolving healthcare market conditions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AFT Pharmaceuticals Declares Fully Imputed Final Dividend
AFT Pharmaceuticals Limited (ASX: AFP) announced a fully imputed final dividend for shareholders following its latest financial year results. The company confirmed a total cash distribution of NZ$0.025 per share, with a gross distribution amount of NZ$0.0347 per share. The dividend will be paid on 3 July 2026, while the record date has been set for 19 June 2026.
The distribution will be funded through retained earnings and income available for distribution, with total dividend payments amounting to approximately NZ$2.62 million. The announcement also confirmed that the dividend is fully imputed at 28%, providing additional tax benefits for eligible shareholders. AFT Pharmaceuticals continues to maintain a shareholder-return strategy while supporting business growth across its pharmaceutical operations. The latest dividend declaration reflects the company’s ongoing focus on financial stability and capital management.
The company also disclosed supplementary distribution and withholding tax details as part of the official notice. Investors will closely monitor AFT’s future earnings performance and dividend sustainability amid evolving healthcare market conditions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au